KR102758660B1 - 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법 - Google Patents

면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법 Download PDF

Info

Publication number
KR102758660B1
KR102758660B1 KR1020207016410A KR20207016410A KR102758660B1 KR 102758660 B1 KR102758660 B1 KR 102758660B1 KR 1020207016410 A KR1020207016410 A KR 1020207016410A KR 20207016410 A KR20207016410 A KR 20207016410A KR 102758660 B1 KR102758660 B1 KR 102758660B1
Authority
KR
South Korea
Prior art keywords
tumor
delete delete
tumors
trt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207016410A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088374A (ko
Inventor
재미 웨이처트
폴 손델
라비 파텔
재커리 모리스
피터 칼슨
레이니어 헤르난데즈
조셉 그루드진스키
Original Assignee
위스콘신 얼럼나이 리서어치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/809,427 external-priority patent/US11633506B2/en
Application filed by 위스콘신 얼럼나이 리서어치 화운데이션 filed Critical 위스콘신 얼럼나이 리서어치 화운데이션
Publication of KR20200088374A publication Critical patent/KR20200088374A/ko
Application granted granted Critical
Publication of KR102758660B1 publication Critical patent/KR102758660B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207016410A 2017-11-10 2018-11-09 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법 Active KR102758660B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/809,427 2017-11-10
US15/809,427 US11633506B2 (en) 2016-07-18 2017-11-10 Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
PCT/US2018/059927 WO2019094657A1 (en) 2017-11-10 2018-11-09 Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Publications (2)

Publication Number Publication Date
KR20200088374A KR20200088374A (ko) 2020-07-22
KR102758660B1 true KR102758660B1 (ko) 2025-01-22

Family

ID=64665595

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016410A Active KR102758660B1 (ko) 2017-11-10 2018-11-09 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법

Country Status (7)

Country Link
EP (1) EP3706808A1 (enrdf_load_stackoverflow)
JP (2) JP2021502368A (enrdf_load_stackoverflow)
KR (1) KR102758660B1 (enrdf_load_stackoverflow)
CN (2) CN111565762A (enrdf_load_stackoverflow)
CA (1) CA3082056A1 (enrdf_load_stackoverflow)
IL (1) IL274518A (enrdf_load_stackoverflow)
WO (1) WO2019094657A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123873A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
MX2022006426A (es) * 2019-11-27 2022-06-22 Gi Innovation Inc Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80.
EP3842097A1 (en) * 2019-12-23 2021-06-30 Koninklijke Philips N.V. Planning radiation therapy using a personalized hematologic risk score
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
PE20221858A1 (es) * 2020-03-26 2022-11-30 Ramirez Fort Marigdalia Kaleth Tratamientos con radiacion ultravioleta
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
KR20240142498A (ko) * 2022-01-28 2024-09-30 퓨전 파마슈티칼즈 인크. Ntsr1-표적화 방사성제약 및 체크포인트 억제제 조합 요법
WO2024258913A1 (en) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207732A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DK1729824T3 (da) * 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere
EP1833514A2 (en) * 2004-12-20 2007-09-19 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
EP2440253B1 (en) * 2009-06-12 2020-05-13 Cellectar, Inc. Alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
EP3334465A1 (en) * 2015-08-12 2018-06-20 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
AU2017300361B2 (en) * 2016-07-18 2024-08-01 Wisconsin Alumni Research Foundation Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination
US20180022768A1 (en) 2016-07-25 2018-01-25 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
EP3487530B1 (en) * 2016-07-25 2024-03-20 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207732A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Also Published As

Publication number Publication date
CN120550150A (zh) 2025-08-29
JP2021502368A (ja) 2021-01-28
CA3082056A1 (en) 2019-05-16
JP2023179556A (ja) 2023-12-19
AU2018366219A1 (en) 2020-06-11
IL274518A (en) 2020-06-30
CN111565762A (zh) 2020-08-21
WO2019094657A1 (en) 2019-05-16
KR20200088374A (ko) 2020-07-22
EP3706808A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
US20250195701A1 (en) Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
KR102758660B1 (ko) 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
KR102396324B1 (ko) 인 시츄 면역 조절 암 백신화를 위한 표적화된 방사선요법 킬레이트
US12109256B2 (en) Radiohalogenated agents for in situ immune modulated cancer vaccination
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
US20110300067A1 (en) Methods for increasing efficacy of radioimmunotherapy of melanoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211103

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230818

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240426

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230818

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240924

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241018

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250117

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250117

End annual number: 3

Start annual number: 1

PG1601 Publication of registration